DEF 14A: PepGen Inc. to Hold Virtual Annual Meeting on June 20, 2024, Proposing Officer Liability Limit Amendment

PepGen Inc. will host its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to vote on key proposals including the election of directors, an amendment to limit officer liability, and the ratification of the company's independent auditor.

Summary

• PepGen Inc. is holding its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 12:00 p.m. Eastern Daylight Time.
• Stockholders of record as of April 22, 2024, are eligible to vote.
• The meeting will address the election of two Class II directors, the approval of an amendment to the company's certificate of incorporation to limit officer liability, the ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2024, and the approval of adjourning the meeting if necessary to secure sufficient votes for the officer liability amendment.
• The board of directors recommends voting FOR all proposals.
• The company is providing proxy materials online, with a Notice of Internet Availability mailed to stockholders starting on or about May 3, 2024.
• As of April 22, 2024, there were 32,390,445 shares of common stock outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are presented in a positive light, particularly the amendment to limit officer liability, which is framed as beneficial for attracting and retaining talent. The overall sentiment is slightly positive due to the focus on corporate governance and future growth.

Positives

• The proposed amendment to limit officer liability could enhance the company's ability to attract and retain qualified officers.
• The board of directors is actively seeking diverse candidates for board positions.
• The company is committed to good corporate governance, as evidenced by seeking stockholder ratification of the independent auditor appointment.
• The company has a compensation recovery policy in place.

Negatives

• If the proposal to amend the Third Amended and Restated Certificate of Incorporation does not pass, the company may be at a disadvantage compared to its peers in attracting and retaining top officer candidates.
• The staggered board structure may delay or prevent stockholder efforts to effect a change of management or a change in control.

Risks

• Failure to achieve a quorum at the Annual Meeting could impede the approval of key proposals.
• The company faces risks inherent in its business, as discussed in the Risk Factors section of its 2023 Annual Report.
• The company is dependent on a license agreement with OUI and MRC, and termination of this agreement could negatively impact the company's product development.

Future Outlook

The company expects its peers to adopt exculpation clauses that limit the personal liability of officers in their certificates of incorporation.

Management Comments

• Our board of directors believes it is important to provide protection from certain liabilities and expenses that may discourage prospective or current directors from accepting or continuing membership on corporate boards and prospective or current officers from serving as officers of corporations.
• Limiting concern about personal risk would empower both directors and officers to best exercise their business judgment in furtherance of stockholder interests.

Industry Context

The proposed amendment to limit officer liability aligns with recent changes in Delaware law and is a common practice among public companies to attract and retain qualified executives.

Comparison to Industry Standards

• The document mentions that PepGen expects its peers to adopt exculpation clauses that limit the personal liability of officers in their certificates of incorporation, suggesting that this is becoming an industry standard.
• The document references several publicly-held biopharmaceutical companies, such as Alnylam Pharmaceuticals, Acceleron Pharma, and Ipsen Biopharmaceuticals, indicating that PepGen operates within a competitive landscape of similar companies.

Management Changes

Corporate Governance

Related Party Transactions

• Entities affiliated with RA Capital Management GP, LLC acquired 3,229,200 shares of PepGen's common stock in the IPO in May 2022 at the initial public offering price of $12 per share.
• Entities affiliated with RA Capital Management GP, LLC acquired 2,557,593 shares of PepGen's common stock in the Follow-on Offering at the purchase price of $10.365 per share.

Stakeholder Impact

• Approval of the officer liability amendment could positively impact shareholders by attracting and retaining qualified officers, potentially leading to improved company performance.
• The election of directors will shape the composition of the board and influence the company's strategic direction.
• The ratification of KPMG LLP as the independent auditor ensures continued oversight of the company's financial reporting.

Next Steps

• Stockholders should vote on the proposals outlined in the proxy statement.
• The company will file the Certificate of Amendment with the Secretary of State of the State of Delaware promptly after the Annual Meeting if the proposed Charter Amendment is approved by our stockholders.
• The company will announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.
• The company will continue to review non-employee director compensation from time to time.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Officer Liability, Director Election, KPMG, Corporate Governance, Stockholders